421 related articles for article (PubMed ID: 26400304)
41. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
42. [Expression and significance of Survivin and Smac in ovarian mucinous tumors].
Wang HX; Chen G; Li GL; Jiang YJ
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):387-90. PubMed ID: 21055155
[TBL] [Abstract][Full Text] [Related]
43. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Chen C; Ge J; Lu Q; Ping G; Yang C; Fang X
J Ovarian Res; 2015 May; 8():28. PubMed ID: 25956476
[TBL] [Abstract][Full Text] [Related]
44. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
45. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
46. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
[TBL] [Abstract][Full Text] [Related]
47. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
48. Huge primary retroperitoneal mucinous cystadenoma of borderline malignancy mimicking an ovarian mass: case report and review.
Bifulco G; Mandato VD; Giampaolino P; Nappi C; De Cecio R; Insabato L; Tarsitano F; Mignogna C
Anticancer Res; 2008; 28(4C):2309-15. PubMed ID: 18751411
[TBL] [Abstract][Full Text] [Related]
49. Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status.
Singh N; Gilks CB; Huntsman DG; Smith JH; Coutts M; Ganesan R; McCluggage WG
Histopathology; 2014 Apr; 64(5):626-32. PubMed ID: 24138090
[TBL] [Abstract][Full Text] [Related]
50. Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas.
An S; Kim MJ; Kim SJ; Sung YN; Kim YW; Song KB; Hwang DW; Kim SC; Hruban RH; Hong SM
Histopathology; 2019 Oct; 75(4):559-567. PubMed ID: 31077597
[TBL] [Abstract][Full Text] [Related]
51. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
Okamoto Y; Tanaka YO; Tsunoda H; Yoshikawa H; Minami M
J Magn Reson Imaging; 2007 Jul; 26(1):94-9. PubMed ID: 17659568
[TBL] [Abstract][Full Text] [Related]
52. Calcifications in mucinous and serous cystic ovarian tumors.
Okada S; Ohaki Y; Inoue K; Kawamura T; Hayashi T; Kato T; Kumazaki T
J Nippon Med Sch; 2005 Feb; 72(1):29-33. PubMed ID: 15834205
[TBL] [Abstract][Full Text] [Related]
53. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
54. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
55. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
56. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
57. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Ryland GL; Hunter SM; Doyle MA; Rowley SM; Christie M; Allan PE; Bowtell DD; ; Gorringe KL; Campbell IG
J Pathol; 2013 Feb; 229(3):469-76. PubMed ID: 23096461
[TBL] [Abstract][Full Text] [Related]
58. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
59. [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
Shi HR; Zhang RT
Ai Zheng; 2009 Aug; 28(8):882-5. PubMed ID: 19664338
[TBL] [Abstract][Full Text] [Related]
60. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
